BDBM50194264 (+/-)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-cis-6,11-dimethyl-N-(2-[1,1'-biphenyl]-4-ylethyl)-2,6-methano-3-benzazocine-8-carboxamide::(6S,11R)-3-cyclopropylmethyl-6,11-dimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine-8-carboxylic acid (2-biphenyl-4-yl-ethyl)-amide::CHEMBL377789::US9656961, Example 00154::cis-rac-3-Cyclopropylmethyl-6,11-dimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine-8-carboxylic acid (2-biphenyl-4-yl-ethyl)-amide

SMILES C[C@H]1C2Cc3ccc(cc3[C@@]1(C)CCN2CC1CC1)C(=O)NCCc1ccc(cc1)-c1ccccc1

InChI Key InChIKey=GZDNGLGWJBOMSN-CHCCDMOGSA-N

Data  13 KI  4 IC50  6 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 10 hits for monomerid = 50194264   

TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50194264((+/-)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-...)
Affinity DataKi:  0.260nMAssay Description:The Ki (binding affinity) for opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50194264((+/-)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-...)
Affinity DataKi:  0.300nMAssay Description:Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation countingMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50194264((+/-)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-...)
Affinity DataKi:  0.300nMAssay Description:Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50194264((+/-)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-...)
Affinity DataKi:  0.300nMAssay Description:Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50194264((+/-)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-...)
Affinity DataKi:  0.300nMAssay Description:Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50194264((+/-)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-...)
Affinity DataIC50:  150nMAssay Description:Antagonist activity at human mu opioid receptor expressed in CHO cell membrane assessed as inhibition of DAMGO-induced [35S]GTPgammaS binding after 6...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50194264((+/-)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-...)
Affinity DataIC50:  3.5nMAssay Description:The Ki (binding affinity) for opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50194264((+/-)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-...)
Affinity DataEC50:  0.850nMAssay Description:The Ki (binding affinity) for opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50194264((+/-)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-...)
Affinity DataIC50:  150nMAssay Description:Antagonist activity against human mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50194264((+/-)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-...)
Affinity DataIC50:  150nMAssay Description:Antagonist activity at human mu opioid receptor expressed in CHO cell membrane assessed as inhibition of DAMGO induced [35S]GTP-gamma-S bindingMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed